PDCD1 and melanoma: In another analysis of randomised controlled trial data, Robert et al. reported no significant differences in PFS or OS among anti-PD-1-treated melanoma patients with irAEs treated with systemic corticosteroids compared to patients with irAEs without corticosteroid need61.